Oyster Point Pharma, Inc. announced the appointment of Dan Lochner as its Chief Financial Officer and John Snisarenko as Chief Commercial Officer. Mr. Lochner and Mr. Snisarenko join the company's roster of industry veterans. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset management focused on healthcare equity investing and fund management.

Mr. Lochner brings a unique perspective to the business based on his extensive experience investing in pharmaceutical and biotechnology companies similar to Oyster Point Pharma while at Goldman Sachs. Mr. Lochner reports to Dr. Nau. Mr. Snisarenko joins Oyster Point Pharma from Shire (now Takeda) where he served as Group Vice President and Head of its ophthalmic business.

Mr. Snisarenko brings extensive experience successfully leading the commercialization of new market entries and expanded indications for approved products. He has led commercial strategy and sales and marketing teams for multiple commercial products, including Xiidra, Lucentis, Rituxan, and Actemra with a demonstrated track record of building high performing teams and generating robust sales growth in highly competitive markets. Mr. Snisarenko brings vast experience in pharmaceutical and biotechnology leadership to the Company.

He is responsible for all commercial strategy and execution for Oyster Point Pharma's growing clinical portfolio, including the launch of OC-01 for Dry Eye Disease, if approved by the FDA. Mr. Snisarenko reports to Dr. Nau.